Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone

S. Ristic, C. Collober-Maugeais, E. Pecher and F. Cressier

Abstract

Aims To compare the effects of nateglinide plus metformin with gliclazide plus metformin on glycaemic control in patients with Type 2 diabetes.

Methods Double-blind, double-dummy, parallel group, randomized, multi-centre study over 24 weeks. Patients with inadequate glucose control on maximal doses of metformin were randomized to additionally receive nateglinide ($n = 133$) or gliclazide ($n = 129$). Changes from baseline in HbA$_{1c}$, fasting plasma glucose (FPG) and mealtime glucose and insulin excursions were examined.

Results HbA$_{1c}$ was significantly ($P < 0.001$) decreased from baseline in both treatment groups (mean changes: nateglinide $-0.41\%$, gliclazide $-0.57\%$), but with no significant difference between treatments. Proportions of patients achieving a reduction of HbA$_{1c} \geq 0.5\%$ or an end point HbA$_{1c} < 7\%$ were also similar (nateglinide 58.1%, gliclazide 60.2%). Changes from baseline in FPG were similarly significant in both treatment groups (nateglinide $-0.63$, gliclazide $-0.82$ mmol/l). Reduction from baseline in maximum postprandial glucose excursion were significant in the nateglinide group only (nateglinide $-0.71$, gliclazide $-0.10$ mmol/l; $P = 0.037$ for difference). Postprandial insulin levels were significantly higher with nateglinide compared with gliclazide. The overall rate of hypoglycaemia events was similar in the nateglinide group compared with the gliclazide group.

Conclusions No significant difference was seen between nateglinide plus metformin and gliclazide plus metformin in terms of HbA$_{1c}$. However, the nateglinide combination demonstrated better postprandial glucose control.

Diabet. Med. 23, 757–762 (2006)

Keywords diabetes mellitus Type 2, gliclazide, HbA$_{1c}$, metformin, nateglinide

Abbreviations AEs, adverse events; AUC, area under curve; BMI, body mass index; FPG, fasting plasma glucose; HOMA, homeostatis model assessment

Introduction

Type 2 diabetes mellitus is a progressive, chronic disease that is increasing in prevalence worldwide, along with a rise in obesity, one of its contributory factors [1]. It is characterized by insulin resistance, causing a decrease in transport of glucose into fat and muscle cells, and by a decrease in insulin secretion from the pancreas [2]. The most frequently used initial pharmacological
agent is metformin, but metformin monotherapy often fails to maintain adequate glucose control over the long term. As a result of advancing deterioration of β-cell function, treatment with more than one agent is usually required over time to achieve and maintain good glycaemic control. Therefore, combining metformin with other therapies such as sulphonylureas is the next step to maintain successful control during the progressive course of the disease [3].

Sulphonylureas act by binding to sulphonylurea receptors on pancreatic β-cells, leading to increased secretion of insulin [4]. Gliclazide is a second generation sulphonylurea that is widely used in the treatment of patients with Type 2 diabetes because it has similar efficacy to other sulphonylureas but a lower risk of hypoglycaemia [5,6]. Nateglinide is a rapid-onset insulinotropic agent unrelated to sulphonylureas [7,8]. Because its effect on insulin secretion subsides when glucose levels fall, nateglinide has less potential to elicit hypoglycaemia than sulphonylureas [9]. Furthermore, nateglinide has minimal or no effect on body weight, also probably because its insulinotropic effects are limited to the postprandial period and thus nateglinide does not increase overall insulin exposure [10].

This study aimed to determine the efficacy and safety of the combination of nateglinide plus metformin with the combination of gliclazide plus metformin, in patients for whom metformin alone had failed to maintain adequate glycaemic control. Gliclazide was selected as the most appropriate comparator because of its lower risk of hypoglycaemia.

Patients and methods
This was a double-blind, double-dummy, parallel group, randomized study carried out over a period of 24 weeks. Patients were recruited from 24 centres across five countries, as listed in the Acknowledgements. The study was carried out according to Good Clinical Practice guidelines and the Declaration of Helsinki. The protocol was approved by the appropriate ethical boards and all patients provided written informed consent. Patients were eligible if they had Type 2 diabetes for a minimum of 6 months and had received metformin monotherapy for at least 3 months; the patients also had to be on a minimum metformin dose of 1000 mg per day continuously for at least 2 months; the patients also had to be on a minimum metformin dose of 1000 mg per day continuously for at least 2 months and had received metformin monotherapy for at least 6 months and had experienced any confirmed hypoglycaemic events (symptomatic and/or asymptomatic events with plasma glucose concentration ≤ 4.0 mmol/l) and if the patient had not experienced more than three hypoglycaemic events in the past month.

Efficacy was determined from the change in HbA1c levels from baseline to end point. Treatments were also assessed for the percentage of patients reaching a treatment target (end point HbA1c < 7% and/or a decrease ≥ 0.5% HbA1c), FPG and body weight after 24 weeks of double-blind treatment. At baseline and after 24 weeks, patients attended the clinic after an overnight fast and received a standard breakfast consisting of 180 ml orange juice (grapefruit juice was not allowed), 60 g of bread (white, wheat or rye), 20 g jam or preserves, 10 g butter or margarine, 120 ml whole milk (3–4% fat) or the equivalent amount of cheese plus 120 ml water, and decaffeinated coffee or tea if desired. The meal was consumed within 15 min and blood samples were taken at 0, 15, 30, 60, 90, 120, 180 and 240 min. Glucose and insulin concentrations were measured and excursions were calculated from the difference between fasting and postprandial levels; the area under the glucose curve from 0 to 4 h (AUC0–4), adjusted for pre-meal values, was calculated for patients who had at least six measurements. In addition, insulin secretion index was calculated as: homeostatis model assessment (HOMA)-B = [20 × fasting insulin (mU/l)]/[fasting glucose (mmol/l) – 3.5].

Determinations of HbA1c and glucose and insulin from the meal tests were carried out at two central laboratories, one in Europe and one in the USA. Additionally, all patients were provided with glucose-monitoring devices and supplies, and were instructed on their use. Hypoglycaemic events were analysed according to whether they were asymptomatic, symptomatic or confirmed events; number of hypoglycaemic clinical symptoms and incidence rate (number of symptoms per 100 patients per month) were also determined. Symptoms suggestive of hypoglycaemia were tachycardia, palpitations, shakiness, sweating and dizziness, hunger, blurred vision, impairment of motor function, confusion or inappropriate behaviour. An event was considered as confirmed if the self-monitored plasma glucose value obtained at the time of the event was ≤ 4.0 mmol/l (corresponding to blood glucose value of ≤ 3.6 mmol/l) or if hypoglycaemia was classified as grade 2 (i.e. an episode with sufficient neurological impairment that the patient was unable to initiate self-treatment and required assistance or hospitalization). The incidence rate of hypoglycaemic events per 100 patients per month was calculated as [(total number of events across all patients)/(total duration on treatment in days)] × 30 × 100. All adverse events were recorded; they were defined as serious if they were fatal, life-threatening, required prolonged hospitalization, resulted in persistent or significant disability/incapacity, constituted a congenital anomaly/birth defect or were considered medically significant. For each adverse event, the relationship to study drug treatment was classified by the investigator as suspected or not suspected.

A planned sample size of 120 patients per treatment was considered sufficient to detect an HbA1c difference of 0.5%...
with 90% power, assuming a dropout rate of 15% and an SD of 1.1. An ANCOVA model was used to test the null hypothesis that nateglinide plus metformin combination therapy was as effective as gliclazide plus metformin combination therapy. The primary ANCOVA model included effects for treatment, study centre, baseline HbA1c and treatment by baseline HbA1c interaction. Efficacy analyses used the intent-to-treat population which included all randomized patients with at least one post-baseline efficacy evaluation, and safety was assessed for all randomized patients with a post-baseline safety assessment. Evaluations from the meal test were assessed for all patients with available data; during storage and transport to the central laboratories a small number of samples were lost and thus numbers of patients with available data were reduced slightly, although analysis indicated that the population with data was equivalent to the total population. The statistical tests were conducted at the two-sided significance level of 0.05.

Results

A total of 262 subjects were enrolled in the study and their demographic details are summarized in Table 1, according to treatment group; 133 were randomized to nateglinide plus metformin and 129 to gliclazide plus metformin. The age, sex and ethnicity profiles were similar across both treatment groups. Most patients were Caucasian, with an overall mean age of 61.8 years and BMI of 29.0 kg/m². Diabetic characteristics at baseline were also comparable for the two treatment groups.

During the study, 33 patients discontinued treatment prematurely; 13 (9.8%) patients from the nateglinide group (two as a result of adverse events, one lost to follow-up, nine who withdrew consent and one because of an unsatisfactory therapeutic effect) and 20 (15.5%) patients from the gliclazide group (eight due to adverse events, four lost to follow-up, six who withdrew consent and two because of protocol violations).

The mean metformin doses at study entry were comparable (1921 and 1812 mg/day in the nateglinide and gliclazide groups, respectively). The majority of patients in the nateglinide group (59.4%) were titrated up to the highest dose level (180 mg three times/day), compared with 35.7% of patients in the gliclazide group attaining the highest dose level (240 mg/day).

Glycaemic control

HbA1c was significantly decreased in both treatment groups when compared with baseline, but there was no difference in efficacy between the two treatment groups (Table 2). The proportion of patients with absolute reductions from baseline in HbA1c of ≥ 0.5% were similar in both treatment groups. End point HbA1c was < 7.0% in slightly fewer patients in the group treated with nateglinide than with gliclazide. However, the proportion of patients achieving either an absolute reduction of HbA1c ≥ 0.5% from baseline or an end point HbA1c < 7.0% was similar for both treatments.

Reductions from baseline in FPG were statistically significant in both treatment groups, but the between-group difference in change from baseline was not statistically significant (Table 2). A small increase in mean body weight of less than 0.5 kg was observed in both groups, but the changes from baseline were not significant in either case and there was no significant difference (P = 0.879) between treatments (data not shown).

Following the test meal, the changes from baseline to 24 weeks in maximum postprandial glucose were statistically significant for both treatment groups, but the between-group difference in change from baseline was not statistically significant (Table 3). However, the decrease from baseline in maximum postprandial glucose excursion was significant in the

Table 1 Demographic and background characteristics by treatment group

|                          | Nateglinide + metformin | Gliclazide + metformin |
|--------------------------|-------------------------|------------------------|
| Age (years), mean ± SD   | 62.0 ± 11.0             | 61.6 ± 10.1            |
| Range                    | 28–84                   | 38–80                  |
| Age group, n (%)         |                         |                        |
| < 65 years               | 70 (52.6)               | 68 (52.7)              |
| ≥ 65 years               | 63 (47.4)               | 61 (47.3)              |
| Sex, n (%)               |                         |                        |
| Male                     | 72 (54.1)               | 65 (50.4)              |
| Female                   | 61 (45.9)               | 64 (49.6)              |
| Race, n (%)              |                         |                        |
| Caucasian                | 131 (98.5)              | 124 (96.1)             |
| Black                    | 0                       | 1 (0.8)                |
| Asian/Chinese/Japanese   | 0                       | 2 (1.6)                |
| Other                    | 2 (1.5)                 | 2 (1.6)                |
| BMI (kg/m²), mean ± SD   | 28.5 ± 3.5              | 29.5 ± 3.6             |
| Duration of diabetes (years), mean ± SD | 7.16 ± 6.30         | 6.70 ± 5.55            |
| Baseline HbA1c (%), mean ± SD | 7.67 ± 0.59             | 7.60 ± 0.58            |
| Baseline FPG [mmol/l], mean ± SD | 8.95 ± 1.49             | 8.73 ± 1.48            |
Table 2 HbA1c changes from baseline to end point, proportion of patients with positive responses to predefined HbA1c criteria and fasting plasma glucose changes to end point

|                                | Nateglinide + metformin | Gliclazide + metformin | Treatment difference |
|--------------------------------|-------------------------|------------------------|----------------------|
| **Baseline HbA1c (%), mean ± sd** | 7.66 ± 0.59             | 7.57 ± 0.57            |                      |
| **Change, least squares mean ± se** | −0.41 ± 0.08           | −0.57 ± 0.08           |                      |
| **P-value for change**           | < 0.001                 | < 0.001                |                      |
| **Treatment difference, mean ± sd** | 0.17 ± 0.10            | 0.099                  |                      |
| **P-value for treatment difference** |                        |                        |                      |

Response rates, n (%)

- **Reduction of HbA1c ≥ 0.5% from baseline**
  - Baseline HbA1c < 7.0%
  - Baseline HbA1c ≥ 7.0%

- **End point HbA1c < 7.0%**
  - Baseline HbA1c < 7.0%
  - Baseline HbA1c ≥ 7.0%

Table 3 Plasma glucose and insulin levels following a test meal, and insulin secretion index (HOMA-B), at study baseline and changes after 24 weeks of treatment of patients with Type 2 diabetes

|                            | Nateglinide + metformin | Gliclazide + metformin | Treatment difference |
|-----------------------------|-------------------------|------------------------|----------------------|
| **Maximum postprandial plasma glucose (mmol/l)** | n = 113                 | n = 107                |                      |
| Baseline, mean ± sd         | 15.19 ± 3.37            | 13.89 ± 3.08           |                      |
| Least squares mean change ± SE | −1.50 ± 0.28          | −1.05 ± 0.30           | −0.45 ± 0.37         |
| P-value                     | < 0.001                 | < 0.001                |                      |
| **Maximum postprandial plasma glucose excursion (mmol/l)** | n = 109                 | n = 104                |                      |
| Baseline, mean ± sd         | 6.21 ± 3.12             | 5.39 ± 2.36            |                      |
| Least squares mean change ± SE | −0.71 ± 0.22          | −0.10 ± 0.23           | −0.61 (0.29)         |
| P-value                     | 0.001                   | 0.663                  | 0.037                |
| **30-min postprandial insulin (pmol/l)** | n = 111                 | n = 107                |                      |
| Baseline, mean ± sd         | 218.2 ± 163.6           | 222.6 ± 182.9          |                      |
| Least squares mean change ± SE | 83.9 ± 16.6            | 39.6 ± 17.8            | 44.3 ± 22.2          |
| P-value                     | < 0.001                 | 0.028                  | 0.047                |
| **2-h postprandial insulin (pmol/l)** | n = 112                 | n = 100                |                      |
| Baseline, mean ± sd         | 152.2 ± 142.2           | 150.2 ± 166.4          |                      |
| Least squares mean change ± SE | 75.5 ± 16.0            | 30.2 ± 16.6            | 45.3 ± 21.1          |
| P-value                     | < 0.001                 | 0.071                  | 0.033                |
| **HOMA-B**                  |                         |                        |                      |
| Baseline, mean ± sd         | 44.6 ± 48.7             | 56.3 ± 68.2            |                      |
| Least squares mean change ± SE | 11.3 ± 5.3             | 17.3 ± 5.3             | −5.9 ± 6.9           |
| P-value                     | 0.033                   | 0.001                  | 0.387                |

P-values are within-group for changes from baseline and between-groups for treatment difference.

Nateglinide group only and the decrease was significantly greater with nateglinide compared with gliclazide (P = 0.037). The postprandial glucose AUCO−4h, adjusted for pre-meal values, was significantly decreased after 24 weeks of treatment in the nateglinide group (−2.20 mmol*h/l; P < 0.001) but the decrease in the gliclazide group (−0.61 mmol*h/l) was not significant; the difference between the changes from baseline did not reach significance (P = 0.054). The changes from baseline in the 30-min and 2-h postprandial insulin level and 2-h insulin excursion were larger in the nateglinide group compared with the gliclazide group. The between-group differences in change from baseline (in favour of nateglinide) were statistically significant for each parameter (Table 3).

The insulin secretion index, as measured by HOMA-B (Table 3), was slightly greater at baseline in the gliclazide group than the nateglinide group, although the standard
deviations were large in each case. A statistically significant increase was observed in both treatment groups after 24 weeks, but the difference between treatments was not significant.

Safety and hypoglycaemia incidence

There were no deaths during the study. The incidence of serious adverse events, as well as of adverse events (AEs) causing dose interruption or dose change, was low and comparable between groups. Discontinuations as a result of AEs appeared to be more frequent in the gliclazide group (eight patients (6.3%)) compared with the nateglinide group (two patients (1.5%)); for nateglinide + metformin, none of the AEs leading to discontinuation were considered related, but for gliclazide + metformin a relationship was suspected in five cases (three abdominal pain, one nausea, one dizziness/malaise). Infections and gastrointestinal disorders were the most frequently reported types of adverse events. No clinically relevant difference for any AE was noted between treatment groups. The incidence of all suspected drug-related AEs was low (6.9 and 7.1% in the nateglinide and gliclazide group, respectively).

The number of patients with at least one event suggestive of hypoglycaemia was similar between treatment groups, and the number of patients with more than one confirmed hypoglycaemic event was similar in the nateglinide group and in the gliclazide group, as shown in Table 4. The number of clinical symptoms of hypoglycaemia was nearly twice as high in the gliclazide group compared with the nateglinide group (15.5 and 28.2 symptoms per 100 patients per month in the nateglinide and gliclazide groups, respectively). In particular, fewer episodes of tremor, sweating and asthenia was reported in the nateglinide group compared with the nateglinide group (15.5 and 28.2 symptoms per 100 patients per month in the nateglinide and gliclazide groups, respectively), tremor (3.3 and 8.6 per 100 patients per month) and asthenia (1.2 and 5.6 per 100 patients and month).

Discussion

The reduction in HbA1c was similar when either nateglinide or gliclazide were added to metformin in patients who were not adequately controlled with metformin monotherapy. The degree to which the HbA1c levels were lowered is in agreement with previous studies investigating the addition of nateglinide to metformin [11], or the combination of another insulin secretagogue with metformin [5,12]. It is of interest to note that, when combined with metformin, essentially equivalent efficacy was achieved with an agent targeting primarily postprandial glucose (nateglinide/metformin reduced postprandial glucose excursion to a greater extent than gliclazide/metformin) and an agent that targets primarily fasting glucose level (gliclazide/metformin reduced FPG to a greater extent than nateglinide/metformin), highlighting the importance of the postprandial period in overall glycaemic exposure [13,14].

The number of patients showing an improvement in HbA1c was similar for both treatments. However, fewer patients in the nateglinide combination group achieved the target HbA1c of less than 7.0% at end point than in the gliclazide group. A small difference in baseline HbA1c, slightly higher in nateglinide plus metformin (7.66%) compared with gliclazide plus metformin (7.57%), may account for this result. Supporting this, the composite efficacy criteria, i.e. merging an improvement of at least 0.5% or achieving an HbA1c less than 7.0%, showed the treatments were comparable.

The changes in FPG concentrations mirrored those observed for HbA1c. Measures of post-prandial glucose control and prandial insulin secretion were either significantly better in the group of patients treated with nateglinide plus metformin or showed a corresponding trend. Control of postprandial hyperglycaemia is believed to have more of an impact on both micro- and macrovascular risk factors than reduction of elevated fasting glucose levels [15]. In a meta-analysis of studies of mortality in relation to glycaemia, the 2-h blood glucose level was more predictive of all-cause and cardiovascular death than FPG [16].

Nateglinide and gliclazide were both well tolerated and the incidence of adverse events was similar in either group. The number of hypoglycaemic events, particularly asymptomatic events, was higher than seen in previous trials with nateglinide. However, this was likely to be because of the recommendation given to patients in the study to measure blood glucose regularly, independent of whether they were experiencing symptoms of hypoglycaemia. Also, the threshold value used to define hypoglycaemia was 4.0 mmol/l, which was relatively high compared with the level used routinely in many other clinical trials.

This is the first systematic comparison of the addition of a meglitinide vs. addition of a sulphonylurea to metformin as combination therapy in patients who were not adequately controlled on metformin monotherapy. A very recently published study in drug-naïve patients given either nateglinide/metformin or glibenclamide/metformin combination treatment from the start also showed similar control of HbA1c, but better...
postprandial control with nateglinide and better FPG control with glibenclamide [17]. The results of the present study showed that adding nateglinide provided similar efficacy to adding gliclazide to metformin for treatment of Type 2 diabetes, with HbA1c reduced to a similar extent by either treatment over the 24 weeks. However, the nateglinide combination reduced glucose excursions and increased insulin concentrations to a greater extent than the gliclazide combination after a test meal. Addition of nateglinide to metformin is an effective treatment for patients inadequately controlled by metformin alone. Further studies are being carried out to assess long-term postprandial glucose control and relationship to diabetic complications.

Competing interests
This study was sponsored by Novartis Pharma, Basel. The authors are employees of Novartis Pharma, Switzerland and EP has company shares. The study protocol was designed by the authors who were also responsible for data collection, analysis and reporting of results.

Acknowledgements
The authors thank Dr Peter Bates, Cambridge Medical Writing Services, CB10 1SH, UK, for help in preparation of the manuscript. The authors would also like to thank the investigators involved in the study: Dr Keith Bowering, Alberta, Dr Chantal Godin, Quebec, Dr Irving Gottesman, Ontario, Dr David Lau, Alberta, Dr Alicia Schiffrin, Quebec, Dr Vincent Woo, Manitoba, Canada; Dr Pierre Cause, Saint Etienne, Dr Michel David, Fabregues, Dr Salam Farhat, St Pierre de Chandieu, Dr Alain Giacominio, Savigny en Veron, Dr Francois Lacoin, Albens, Dr Michele Pithon, Hyeres, France; Dr Maurizio Bevilacqua, Milan, Dr Laura Corsi, Chiavari, Professor Ottavio Giampietro, Pisa, Professor Italo Tanganelli, Sienna, Professor Giorgio Viviani, Genova, Italy; Dr Isabel Chico, Barcelona, Dr Francisca Fernandez, Girona, Dr Jose Miguel Gonzalez, Barcelona, Dr Joan Martorell, Lerida, Dr Andreu Nubiola, Barcelona, Dr Luis De Teresa, Alicante, Spain; and Dr Gertrud Kacerovsky-Bielesz, Vienna, Austria.

References
1 Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782–787.
2 James DE. MUNC-ing around with insulin action. J Clin Invest 2005; 115: 219–221.
3 Ward AJ, Salas M, Caro JJ, Owens D. Health and economic impact of combining metformin with nateglinide to achieve glycemic control: comparison of the lifetime costs of complications in the UK. Cost Eff Resour Alloc 2004; 2: 2–10.
4 Cheng AY, Fantus IG. Oral anti-hyperglycemic therapy for type 2 diabetes mellitus. Can Med Assoc J 2003; 172: 213–226.
5 Garber AJ. Using dose–response characteristics of therapeutic agents for treatment decisions in type 2 diabetes. Diabetes Obes Metab 2000; 2: 139–147.
6 Lindblad U, Melander A. Sulphonylurea dose–response relationships: relation to clinical practice. Diabetes Obes Metab 2000; 2: 25–31.
7 Hirschberg Y, Karara AH, Pietri AO, McLeod JF. Improved control of mealtime glucose excursions with co-administration of nateglinide and metformin. Diabetes Care 2000; 23: 349–353.
8 Pratley R, Foley J, Dunning B. Rapid-acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control. Curr Pharmaceut Design 2001; 7: 955–961.
9 Fonseca VA, Kelley DE, Cefalu W, Barzon MA, Purkayastha D, Nestler JE et al. Hypoglycemic potential of nateglinide versus glyburide in patients with type 2 diabetes mellitus. Metabolism 2004; 53: 1331–1335.
10 Hollander PA, Schwartz SL, Haas SJ, Zheng H, Foley JE, Dunning BE. Importance of early insulin secretion. Diabetes Care 2001; 24: 983–988.
11 Marre M, Van Gaal L, Usadel KH, Ball M, Whatmough I, Guitard C. Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients. Diabetes Obes Metab 2002; 4: 177–186.
12 Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S. Improved glycaemic control by addition of glimepiride to metformin monotherapy in Type 2 diabetic patients. Diabet Med 2001; 18: 828–834.
13 Saloranta C, Guitard C, Pecher E, de Pablos-Velasco P, Lahtti K, Brunel P et al. Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a pre-diabetic population. Diabetes Care 2002; 25: 2141–2146.
14 Whitelaw DC, Clark PM, Smith JM, Nattrass M. Effects of the new oral hypoglycemic agent nateglinide on insulin secretion in Type 2 diabetes mellitus. Diabet Med 2000; 17: 225–229.
15 Home P. Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes. Curr Med Res Opin 2005; 21: 989–998.
16 The DECIDE Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397–404.
17 Gerich J, Raskin P, Jean-Louis L, Purkayastha D, Baron MA. Two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care 2005; 28: 2093–2099.